医药板块震荡调整，关注恒生创新药ETF（159316）、港股通医药ETF（513200）等投资机会

Core Viewpoint - The pharmaceutical sector is experiencing fluctuations, with major indices showing declines, while the Hang Seng Innovation Drug ETF has seen significant inflows, indicating investor interest in innovative drug companies. Group 1: Market Performance - As of the midday close, the CSI 300 Pharmaceutical and Health Index fell by 1.0% [1] - The CSI Innovation Drug Industry Index and the Hang Seng Hong Kong Stock Connect Innovation Drug Index both decreased by 0.7% [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index dropped by 0.5% [1] - The CSI Biotechnology Theme Index declined by 0.4% [1] Group 2: ETF Inflows - The Hang Seng Innovation Drug ETF (159316) recorded a net subscription of 25 million units in the first half of the day [1] - According to Wind data, the Hang Seng Innovation Drug ETF has attracted nearly 1.2 billion yuan in inflows this month, ranking first among Hong Kong stock innovation drug-related products [1] Group 3: Index Composition - The CSI Innovation Drug Industry Index focuses on leading innovative drug companies in A-shares, consisting of no more than 50 stocks primarily involved in innovative drug research and development [6] - The CSI Biotechnology Theme Index targets leading biotechnology companies in A-shares, including those involved in gene diagnostics, biopharmaceuticals, and blood products [8] - The CSI 300 Pharmaceutical and Health Index encompasses leading companies in the pharmaceutical and health industry, covering segments such as chemical pharmaceuticals, medical services, and medical devices [9]